Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Our latest clients all have the potential to grow significantly in the near and long-term future

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Nov 08, 2017 6:44 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Enters the Multibillion-Dollar Tea Market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to use that technology in the tea market. The company plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. An article discussing this reads: “Lexaria’s acquisition of Poviva Tea, LLC, announced on November 2 (http://nnw.fm/CQpn9), gives Lexaria a toehold in this vast $7 billion-plus market and consolidates ownership of Poviva Tea, LLC as a wholly owned Lexaria Bioscience subsidiary. The move also simplifies future operations and certain intellectual property ownership issues. In addition, Lexaria announced that, effectively immediately, PoViva Tea will now operate with the trade name of ViPovaTM Tea. The company believes that the rebranding will ensure long-term protection of intellectual rights. At the center of this strategy is Lexaria’s patented DehydraTECH technology, which is focused on improving the delivery of many commonly used Active Pharmaceutical Ingredients (APIs). The DehydraTECH technology provides an additional layer of effectiveness, designed to harmonize with the intellectual property of third parties, which both patented and generic API substances can employ. Lexaria’s long term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Nov 09, 2017 7:12 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Filing of New Patent Application with USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Existing products occupying this space include Viagra™ (sildenafil) and Cialis™ (tadalafil). Per the update, a common complaint regarding existing PDE5 inhibitors relates to the slow-acting nature of the substances. Lexaria believes that its patented DehydraTECH™ technology, building on existing research with cannabinoid delivery, will allow for faster-acting treatments in many cases utilizing lower dosage quantities. Separately, Lexaria this morning announced that a number of existing stock options and warrants have been exercised, with the company receiving a total of $69,736.50 from the transaction.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Nov 13, 2017 6:08 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Covered in November ‘Let’s Toke Business’ Report Alongside Canopy Growth (TSX: WEED)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has been featured in the November issue of ‘Let’s Toke Business.’ The report draws similarities between Lexaria and Canopy Growth (TSX: WEED), as both companies have had major breakouts on the stock market recently. The ability of Lexaria’s technology to expand into other markets was mentioned in the report, as well the possibility that non-cannabis applications could demonstrate an even greater potential. On November 9, Lexaria announced that it filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Based on existing research with cannabinoid delivery, Lexaria believes that its patented DehydraTECH™ technology will enable faster-acting treatments in many cases utilizing lower dosage quantities.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Nov 27, 2017 6:14 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Present at LD Micro Main Event; Reports Warrant Exercise

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it will be presenting at the upcoming 10th annual LD Micro Main Event taking place December 5-7 in Los Angeles, California. Additionally, the company is filing its annual Form 10K which includes financial statements that will be available today at the Securities and Exchange Commission's website (http://www.sec.gov). Lexaria also said that through the exercise of warrants and a compensation option certificate previously granted, the company has received US $118,913. The compensation option certificate was exercised at the price of $0.42 and the stock warrants were exercised at prices of $0.14, $0.273, and $0.60 for a total of 415,187 common shares being issued.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Nov 29, 2017 5:38 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

- Proprietary lipophilic enhancement technology boosts bioavailability of orally ingested cannabinoids and masks unpleasant taste
- Only company in the world to obtain a patent for improved oral or ingestible delivery of all cannabinoids, including both non-psychoactive and psychoactive
- Company generates revenue from out-licensing its technology

The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit.

Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids. The body’s gastrointestinal tract poorly absorbs cannabinoids—whether ingested in pill form or via cannabis edibles—so smoking as a means of cannabis administration has been the norm for many users in order to achieve greater effectiveness. Lexaria’s technology, however, enables the body to derive greater effect from orally administered cannabinoids without the vehicle of smoking. The company’s patented process increases bio-absorption of cannabinoids by between five- and ten-fold and, additionally, reduces onset time by about 75 percent.

In addition to poor absorption, a second hindrance exists when it comes to orally administrated cannabis, and that is an unpleasant taste that accompanies it. Companies that manufacture edible cannabis products have been forced to mask this disagreeable attribute with an overabundance of sweeteners, which adds an unhealthy element to the products and still isn’t enough to completely subdue the repellent taste. Lexaria’s technology combats this problem by effectively and thoroughly masking the unpleasant flavor of cannabis.

The company’s lipophilic enhancement technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and it’s patent-allowed for tetrahydrocannabinol (THC) and all other psychoactive cannabinoids, as well as non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and more.

Lexaria is, to date, the only company in the world to be awarded a patent for the improved oral or ingestible delivery of all cannabinoids, including pill form, beverages and edibles. The company has patents relating to its technology in both the United States and Australia and, additionally, has a portfolio of 19 national and regional patent application filings in 44 other countries.

Lexaria generates revenue by out-licensing this technology and is positioned to now out-license it at a considerable royalty rate as a partner to biopharmaceutical companies rather than a competitor. The company foresees this generating substantial new business opportunities in 2018.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Dec 01, 2017 7:21 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Stock, Option and Warrant Transactions

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced various stock, option and warrant transactions. The news release states, “Following issuance of these common shares, Lexaria will have 69,674,919 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.” No shares were sold or registered in the United States. In addition, John Docherty, President of Lexaria Bioscience Corp., recently issued a clip discussing the company's technology that allows for the enhanced flavor and faster absorption of edible products (http://nnw.fm/M5w5w).
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Dec 04, 2017 5:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

- Major interest generated in Lexaria’s technology at MJBizCon
- Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect
- Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience

This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand for improved edible products in the market, with dispensary owners showing a refreshingly new willingness to carry CBD-based edibles on their shelves and manufacturers displaying a keen interest in Lexaria’s patented DehydraTECH™ delivery technology to incorporate in their products. To accommodate all of the interest shown, as well as requests for business discussions, the company intends to expand its sales team and infrastructure.

Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids, including CBD, as well as for the delivery of THC and other psychoactive cannabinoids. This delivery technology masks the taste of edibles, eliminating the need for unhealthy sugars and sweeteners used in many products to mask bitter flavors. It also increases bio-absorption of cannabinoids and other active compounds by up to 10 times and reduces the time of onset of effects, which were previously typically 60 to 120 minutes, to between 15 and 20 minutes. These capabilities are in marked contrast to other technologies through which active compounds are bad tasting upon oral intake, broken down by the liver, largely destroyed by stomach acid and unable to cross the intestinal wall to any significant degree.

In August 2015, Lexaria initiated an in vitro study which showed an increase of up to 499 percent in CBD bioabsorption in human intestinal tissues using its technology. In February 2017, Lexaria signed a collaboration agreement with Canada’s National Research Council to investigate the bioavailability enhancement of lipophilic active ingredients and to determine the best methods for processing these active compounds within foods. The company’s patents include a wide range of lipophilic active compounds that can be formulated and delivered using the company’s technology, including cannabinoids, vitamins, NSAIDs and nicotine. They also cover numerous product dosage forms, including foods, liquids, emulsions, tablets and capsules.

Lexaria prides itself on being a technology disruptor in the rapidly emerging cannabis market. For manufacturers, it reduces the cannabinoid per serving unit cost, or it can deliver stronger effects in environments where serving levels are regulated. Consumers benefit greatly from the better taste of edibles and the reduced time to effect. Lexaria has developed several CBD-based products for demonstration, testing and sales, including protein energy bars, CBD tablets, exotic teas and TurboCBD™ high absorption hemp oil capsules. To date, the company has signed royalty agreements with several companies in the United States and Canada.

Overall, Lexaria’s technology enables the lowest cost per serving and best consumer experience, which are major benefits for manufacturers of edibles in an increasingly competitive market. Judging by the level of interest in Lexaria’s patented technology generated at MJBizCon, the company is headed for a very bright future.

For more information, visit the company’s website at www.LexariaBioscience.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Dec 07, 2017 5:15 pm

Merger and Acquisition Activity is Heating Up in the Cannabis Industry

NetworkNewsWire Editorial Coverage: Merger and acquisition (M&A) activity in the cannabis industry is heating up, and market analysts point to several important factors contributing to increased activity. Profit is always a central issue, and as the founders of companies established years ago seek attractive exit strategies, new players are considering ways to enter the field in a profitable way. The rapid evolution of technology and its increasing application also serve as catalysts for M&A, as larger companies pursue opportunities that are positioned for current or near-term commercial availability. Such expertise and assets developed by smaller brands could potentially turn them into attractive targets for M&A activity. Lexaria Bioscience Corp. (OTCQB: LXRP) (LXRP Profile) is one such potential target due to its proprietary technology for improved taste, rapidity and delivery of bioactive compounds, including cannabinoids. Other industry reps that have made valuable contributions to cannabis product development include Canopy Growth Corp. (OTC: TWMJF) (TSE: WEED), Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB), Radient Technologies, Inc. (CVE: RTI) and Hemp, Inc. (OTC: HEMP).

As Canada prepares to legalize the recreational use of marijuana next summer, the push for M&A becomes even greater. Since the beginning of the fourth quarter of 2016, an average of approximately 3.2 deals have been closing per week well into 2017 (http://nnw.fm/vC8CU). In comparison, the average for the same period one year ago was approximately 1.4 deals. Analysts note an increase in interest from Canadian companies that wish to cross the border to become a part of the U.S. cannabis industry.

Generally, M&A activities focus on companies and facilities that already have well-developed positions in the field. In 2017, one of the oldest marijuana dispensaries in Denver sold to a Colorado enterprise (http://nnw.fm/ur6vC). The fate of the two-best selling marijuana retailers in Washington was similar. The initial price tag set for the two businesses was $50 million (http://nnw.fm/UTn2Y). Developments on the Canadian market have also been pretty dynamic in 2017. The trend will potentially be upheld in the year to come and strategic interest will fall on innovators in the field of cannabis extraction and CBD oil delivery.

For Lexaria Bioscience Corp. (OTCQB: LXRP), the company has several notches in its belt that could stimulate its potential as an attractive acquisition target. Lexaria is a revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods. The primary differentiator between Lexaria’s products and others on the market is the company’s patented delivery technology for non-psychoactive cannabinoids.

In addition to being cost effective, the company’s DehydraTECH™ proprietary technology has been proven in both the laboratory and market to enhance the performance of beneficial compounds in ingestible products in what regards smell, taste, action duration and bio-availability and absorption. This allows for lower overall dosing and higher efficacy, a plus for cannabis suppliers and consumers alike.

The technology works with all ingested forms of cannabinoids, making Lexaria an enabler rather than a competitor, and allowing the company to develop partnerships with various biotech companies for cannabinoid research and development.

In October, Lexaria grew its portfolio of 19 international patent applications when it received patent allowance for DehydraTECH™ as a delivery platform for all cannabinoids, including (tetrahydrocannabinol) THC, fat soluble vitamins, non-steroidal anti-inflammatory pain medications (“NSAIDs”) and even nicotine. Upon formal patent issuance, the company will receive protection for its technology until at least 2035, and Lexaria will be in the prime position to accelerate its technology out-licensing activities in several key markets.

“This wide-ranging patent allowance from the USPTO exceeds our expectations. This vastly expanded intellectual property protection will enable us to aggressively pursue new business opportunities in 2018 such as what could be the world’s first nicotine edibles for the smokeless tobacco industry, or enhanced products for NSAID-derived pain management, as well as in the rapidly growing cannabis market,” Lexaria CEO Chris Bunka stated in the press release (http://nnw.fm/2iPIn).

Because Lexaria’s patented lipid-delivery technology can be successfully applied to cannabinoids, vitamins, NSAIDs and also tobacco, the company is positioned for opportunity in several lucrative markets.

Global demand for tobacco and nicotine products continues to grow, placing the global tobacco market at approximately $770 billion. However, demand for alternative tobacco and nicotine products aimed at reducing the risks of smoking is also growing at a rapid pace. Lexaria’s technology offers a safer, healthier alternative to traditional nicotine delivery systems by allowing the infusion of nicotine molecules with different edible food ingredients or in capsule formats (http://nnw.fm/Xqw5T). Edible or capsule forms of nicotine have largely been unsuccessful so far in terms of manufacturing, but Lexaria’s technology can overcome any such challenges and lead to the creation of nicotine-infused products without any dangerous side effects.

Currently, Lexaria is the only company in the world that holds a patent for the improved delivery methodology. The patent is valid for the U.S. and Australia, and it is currently pending for 40 other countries. As the company’s market reach and application of technology grow, so does brand recognition and its visibility among larger companies looking to add to their portfolios. This puts Lexaria in an advantageous position when it comes to strategic industrial partnerships and possible acquisition or merger.

Another sweet spot for Lexaria is Canada’s increasing favor toward cannabis. Canadian regulators in November 2017 began discussing the legalization of cannabinoid edibles and beverages for the first time, and the Canadian government has committed to the date of July 1, 2018, for the nationwide legalization of recreational marijuana. As regulators open up the markets in 2018 and 2019, Canadian licensed cannabis producers are facing explosive demand for their products, and could significantly benefit from Lexaria’s delivery platform.

A recent investment into Canopy Growth (OTC: TWMJF) (TSE: WEED) by Constellation Brands, the $40+ billion company behind Corona, Modelo and Svedka is one example of how M&A activity within cannabis is crossing borders into the likes of tobacco and alcohol, as Canada prepares to legalize marijuana for recreational use (http://nnw.fm/zkGu5).

Canopy Growth has long been open to industry partnerships and business interactions aimed at stabilizing its market position. In November 2017, the company announced a distribution agreement with the Winnipeg-based Delta 9 Cannabis Inc. Delta 9 focuses its activity on growing small batch medical cannabis strains for the purpose of developing a diversified range of products. Also in November, Canopy Growth entered another strategic partnership with Green House Holding North America Inc. and GHSC Trading B.V. for the purpose of bringing new products to the Canadian market.

Notably, Lexaria’s patented technology could ensure leading market positions for businesses like Canopy Growth, potentially serving as the fine line between success and failure in an increasingly competitive environment.

Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB) is another prominent player on the Canadian market that demonstrates increased M&A and investment activity in the cannabis industry. Aurora on November 24 announced the launch of a takeover bid for CanniMed, which will enable the company to benefit from Aurora’s leadership position in the Canadian cannabis market. Just a day earlier, Aurora announced its acquisition of H2 Biopharma, a company recognized for its 48,000-square-foot cannabis production facility located in the vicinity of Montreal. Also on November 23, Aurora Cannabis announced the acquisition of Larssen Ltd. – a company known for the creation of high-quality automated greenhouses.

Earlier this week Aurora Cannabis said it will increase its investment in Radient Technologies (CVE: RTI) to a total of $12 million, echoing the need for increased supply in the Canadian market.

“With multiple Aurora facilities coming online and ramping up production in the coming quarters, as well as the anticipated export of cannabis oils and preparations for the legalization of adult consumer use in Canada, Radient’s planned expansion positions both companies exceptionally well to accelerate revenue growth,” Aurora Cannabis CEO Terry Booth stated in the news release (http://nnw.fm/JYs3k). “This investment reflects our strategy to build a constellation of vertically integrated partners and subsidiaries, and we look forward to jointly pursuing further expansion of market share in this exiting space.”

M&A activity isn’t just commonplace among industry giants like Constellation Brand or Aurora Cannabis. Hemp, Inc. (OTC: HEMP) recently announced its acquisition of specialized equipment and technology for enhancing the company’s extraction operation that will be assembled shortly. Currently, Hemp Inc. has the largest multi-purpose industrial hemp processing facility in the Western Hemisphere with many investments in innovation as well as acquisitions of specialized equipment over a long-time period. In August 2017, the company got its NuAxon Tech CO2 supercritical extractor – an essential step towards the completion of thorough extraction infrastructure that will allow for more efficient CBD oil product manufacturing.

M&A activity will focus on unique assets and well-established facilities with the potential to guarantee leadership positions on both the Canadian and the international markets. As regulators continue to open up the cannabis industry, they could fuel even higher rates of activity in 2018 and beyond. For companies like Lexaria, this could mean an exponential amount of potential for licensing agreements, key partnerships and potential acquisition activity.

To find out more about Lexaria Bioscience Corp. visit the company online at Lexaria Bioscience Corp. (OTCQB: LXRP)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Dec 08, 2017 8:12 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

- Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry
- LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products
- Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications

Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as well as existing products and applications, and allows LXRP and stakeholders to participate, on a global scale, in the medical marijuana market that is expected to reach a value of USD $55.8 billion by 2025 according to a report by Grand View Research, Inc. (http://nnw.fm/eIsy5)

John Docherty, President of Lexaria Bioscience Corp., recently issued a video clip discussing the company’s innovative technology that allows for the enhanced flavor and faster absorption of edible products. He discussed opportunities LXRP stakeholders have in commercial applications via third-party licensing in order to leverage the innovative technology to improve delivery and performance of various products in a cost-effective manner (http://nnw.fm/M5w5w).

LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids and carriers, then dehydrated in order to not only accommodate delivery via taste receptors but also accelerate effects as well as intestinal absorption (with accelerated rate of absorption up to 10 times), providing an improved consumer experience and lower cost per dose.

Lexaria’s CBD-based products include tablets, protein energy bars, teas and TurboCBD™ high absorption hemp oil capsules. To date, LXRP has signed royalty agreements with several companies in the United States and Canada for licensed use of its patented technology.

Lexaria is the only company in the world that has been awarded a patent in the United States, Canada, and Australia, for the improved (oral or ingestible) delivery of all non-psychoactive cannabinoids (including liquid emulsions, tablets, capsules, etc.), in addition to delivery of THC and other psychoactive cannabinoids. Additional patents are pending in 40 more countries for use worldwide in an array of applications.

LXRP’s technology is a complimentary layer that works within all research and development applications of cannabinoids in the growing global market. As a result, the technology enables efficacy and results in delivery across a broad spectrum of uses.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Sat Dec 09, 2017 7:55 am

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids, including CBD, as well as for the delivery of THC and other psychoactive cannabinoids. This delivery technology masks the taste of edibles, eliminating the need for unhealthy sugars and sweeteners used in many products to mask bitter flavors. It also increases bio-absorption of cannabinoids and other active compounds by up to 10 times and reduces the time of onset of effects, which were previously typically 60 to 120 minutes, to between 15 and 20 minutes. These capabilities are in marked contrast to other technologies through which active compounds are bad tasting upon oral intake, broken down by the liver, largely destroyed by stomach acid and unable to cross the intestinal wall to any significant degree.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Dec 11, 2017 6:30 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sets its Sights on Booming Global Cannabis Industry

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) patented delivery technology, DehydraTECH™ has positioned the company at the forefront of the thriving global cannabis industry. A recent article discussing this reads: “LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids and carriers, then dehydrated in order to not only accommodate delivery via taste receptors but also accelerate effects as well as intestinal absorption (with accelerated rate of absorption up to 10 times), providing an improved consumer experience and lower cost per dose.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Dec 13, 2017 7:10 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Granted U.S. Patent Regarding DehydraTECH™ Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office ("USPTO") increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs"), and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market," Lexaria Bioscience chief executive officer Chris Bunka stated in the news release.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Dec 15, 2017 4:46 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Launches New Research Programs

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it is engaging in a new topical skin cream research and development ("R&D") program; R&D regarding nicotine edibles; and provided an update on existing R&D programs. The company has developed topical cream products for the delivery of cannabinoids as an addition to its DehydraTECH™ technology. Laboratory testing for human skin absorption and penetration characteristics are scheduled for early 2018 for various formulations. Following its recent nicotine patent grant, Lexaria is advancing its research focus on edible forms of nicotine that could utilize the company’s DehydraTECH™ technology. Additionally, Lexaria plans to further expand its product line in 2018 through working on new and improved formulations for a variety of food products.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Dec 22, 2017 4:58 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

- Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years
- Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids
- Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect

Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017 Marijuana Business Conference & Expo (MJBizCon) in Las Vegas, Lexaria’s chairman and CEO Chris Bunka offered some thoughts on the future of cannabis during an interview with The Street at the LD Micro conference in Los Angeles last week.

“The market potential of cannabis is really exploding worldwide, it’s not just an American phenomenon, it’s happening in Canada, Mexico, Germany, Australia, all over the world,” Bunka told The Street’s Kinsey Grant (http://nnw.fm/JKU2t). “It’s expected to be in the $30-$50 billion range in the next three to four years … and growing very, very rapidly.”

Lexaria BioScience’ss groundbreaking technology is specifically created for the delivery of APIs, or active pharmaceutical ingredients, found in cannabis, vitamins, non-steroidal anti-inflammatory drugs and, even, nicotine.

“We effectively help CBDs get into the bloodstream more rapidly and more efficiently than they otherwise can,” Bunka told Grant in the interview. “We’ve developed this technology – we’re really a research and development company – and we license it off to other companies that have expertise in developing consumer products or cannabis-related products, and they utilize our technology to make those products better.”

The company’s DehydraTECH™ proprietary technology is not only cost effective, it has been proven to enhance the performance of beneficial compounds in ingestible products (http://nnw.fm/jO6ik). An edible cannabinoid product, for instance, becomes better tasting, better smelling, has better bioavailability and absorption, and lasts longer when Lexaria’s patented delivery technology is utilized. Because Lexaria’s technology enables or works with all ingested forms of cannabinoids, the company is seen as an attractive partner with various biotech companies conducting cannabinoid research and development, and it could be an equally attractive acquisition target (http://nnw.fm/D9f9J).

Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria additional future growth potential.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Dec 26, 2017 6:13 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Exploit the Cannabis Industry Utilizing Proprietary Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is well positioned in the booming cannabis industry with its patent-protected technology, DehyraTECH™, which enables a more efficient delivery and absorption of cannabinoids. An article discussing this reads: “Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria additional future growth potential.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Dec 27, 2017 4:39 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018

- DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more
- LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries
- Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of its hemp oil cannabidiol (CBD) products, ranging from branded protein energy bars to premium teas

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://nnw.fm/xrE2r) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the intellectual property (IP) for its next-generation drug delivery system.

“I probably think the company is more undervalued today than it was in the past,” Bunka stated in the interview. “It is potentially world-changing. The potential could deliver aspirin or Ibuprofen better than anyone else. That’s very profound.”

LXRP is a food bioscience company based in Kelowna, British Columbia, Canada, that is a technology disruptor for edible CBD. It markets a high absorption hemp oil formula, protein energy bars, exotic teas and high absorption hemp oil capsules to help the human body absorb CBD. Through potential partnerships, LXRP is now working on applying its technology to improving ingestion of several new products, such as beer, candies, cookies, capsules and pills. It owns international patent rights and has pending patents for its technology changing the way cannabinoids enter the body. Its technology provides increases in intestinal absorption rates, lower dosage size, more rapid delivery to the bloodstream and important taste-masking benefits.

Bunka also said the market does not completely understand the breadth and importance of the patent LXRP received, which also provided patent protection for potential treatment of Alzheimer’s disease, Parkinson’s disease, heart disease, opioid addition and more.

In summary, Bunka said, “The best is absolutely still to come in 2018, and I think it is going to make 2017 look boring in comparison.”

For more information, visit the company’s website at www.LexariaBioscience.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jan 02, 2018 6:06 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Marks Milestone with Patent Approval

- LXRP awarded broad-ranging U.S. patent for novel DehydraTECH™ drug delivery system
- Already scientifically proven to increase efficacy of cannabinoids
- IP protection opens myriad business opportunities

Food bioscience company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) just hit another major milestone in the disruption of drug delivery and administration. With 19 international patent applications filed encompassing 44 countries, Lexaria recently announced its reception of a broad-ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients (http://nnw.fm/x4x3C). The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. As the ramifications of this milestone begin to reverberate in the market, Lexaria is continuing to advance all of its other patent applications around the world while leveraging its patent success in the U.S.

Award of the patents come as little surprise, since Lexaria’s DehydraTECH™ technology has been laboratory and market proven to enhance the performance of beneficial compounds in ingestible products. The speed with which the patent was awarded and the breadth of its utilization in other sectors could be viewed as an indication of the importance of the technology. Lexaria’s lipophilic delivery platform, scientifically shown to enhance absorption of orally-ingested cannabinoids, is believed to be applicable across a wide range of different vitamins, drug types and various cannabinoids, dramatically impacting bioabsorption and bioavailability, as well as taste, smell and speed of action. The recently granted U.S. patent solidifies Lexaria’s position as a disruptive force in innovative drug delivery platforms.

In a news release, Chief Executive Officer Chris Bunka stated, “Lexaria has now locked-up the IP for its next-generation drug delivery system. This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world’s first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market.”

Lexaria’s DehydraTECH™ technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers and can be used with both patented and generic pharmaceutical substances. This breakthrough plays into Lexaria’s long term strategy to partner with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery more predictable, safer and more effective.

For more information, visit the company’s website at www.LexariaBioscience.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Jan 03, 2018 6:56 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Highlights Hidden Value of Wide-ranging DehydraTECH™ Patent

Based in Kelowna, British Columbia, Canada, food bioscience company Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is a technology disruptor for edible CBD. An article discussing this reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://nnw.fm/xrE2r) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the intellectual property (IP) for its next-generation drug delivery system. … Bunka also said the market does not completely understand the breadth and importance of the patent LXRP received, which also provided patent protection for potential treatment of Alzheimer’s disease, Parkinson’s disease, heart disease, opioid addition and more.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Jan 04, 2018 5:15 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Trading on OTCQX Best Market

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, this morning announced that Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has qualified to trade on the OTCQX® Best Market. Subsequently, Lexaria has upgraded from the OTCQB® Venture Market, beginning today. “Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria expects to provide greater visibility and liquidity for our investors on OTCQX as we build our disruptive technology innovations through 2018 and beyond.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Jan 08, 2018 6:27 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Recaps 2017 Highlights

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced the release of a 2017 year-end summary penned by CEO Chris Bunka. The release highlights what Bunka refers to as Lexaria’s “busiest and most productive” year to date, including details about the company’s progress toward strengthening its balance sheet, ongoing research and development efforts related to its patented DehydraTECH™ absorption and palatability enhancing technology, its preparations for increased demand in both Californian and Canadian markets and its ongoing efforts to strengthen its intellectual property portfolio. Bunka concludes the review by looking ahead to Lexaria’s plans for 2018, including efforts to utilize its patented technology to produce increased corporate revenues.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1506
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

PreviousNext

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 2 guests

cron